Navigation Links
'Headache' Publication Describes Potential Mechanistic Rationale for LEVADEX(TM) Favorable Adverse Event Profile

MOUNTAIN VIEW, Calif., Sept. 22 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced publication of results from an in vitro study of its novel LEVADEX(TM) (MAP0004) orally inhaled migraine therapy in development exploring the potential mechanism by which the pharmacokinetics (PK) and pharmacodynamics of LEVADEX may produce fewer adverse events than those seen with intravenous dihydroergotamine (DHE). Results will be published in a manuscript titled Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential Mechanism in an upcoming issue of Headache: The Journal of Head and Face Pain and are available currently in the online version.

LEVADEX, a novel formulation of DHE that is administered via oral inhalation using the company's proprietary TEMPO(R) inhaler, recently met all four primary endpoints in the efficacy portion of a Phase 3 clinical trial. As presented in a late-breaking session at the 14th Congress of the International Headache Society, in the trial LEVADEX provided therapeutic levels of DHE but with lower rates of adverse events, such as dizziness, nausea and paresthesia, than those historically seen with intravenous dosing of DHE.

The in vitro study measured receptor binding and functional activity of DHE at the maximum plasma concentrations (Cmax) achieved in human PK trials after IV administration or after LEVADEX inhalation. The IV DHE Cmax was at least ten times higher than LEVADEX Cmax while the AUCs were approximately the same. The lower LEVADEX Cmax was associated with markedly different receptor binding and functional activity. LEVADEX provided Cmax levels sufficiently high to trigger anti-migraine receptors to the same degree as IV dosing, but did not stimulate receptors thought to be responsible for the adverse event profile characteristics of IV DHE.

"We believe that these receptor studies could explain the lower adverse event incidence seen in clinical trials with LEVADEX to date because of the novel pharmacokinetic profile of our formulation and delivery method," said Shashidhar H. Kori, M.D., vice president of clinical development and medical affairs of MAP Pharmaceuticals. "In Phase 2 and Phase 3 clinical trials, LEVADEX has shown the potential to provide rapid and sustained relief of migraine symptoms and good tolerability for patients. Based on our receptor studies and clinical trials to date, we believe that LEVADEX has the potential to provide a treatment alternative for the many patients who suffer from the debilitating effects of migraine."


LEVADEX orally inhaled migraine therapy is a novel migraine therapy in Phase 3 development. Patients administer LEVADEX themselves using the company's proprietary TEMPO inhaler. LEVADEX has been designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergotamine (DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines. Based on clinical results, the company believes that LEVADEX has the potential to provide both fast onset of action and sustained pain relief and other migraine symptom relief in an easy-to-use and non-invasive at-home therapy.

LEVADEX is designed to incorporate the multiple beneficial mechanisms of action that allow DHE to block initiation of migraine, limit pain, reduce inflammation and stop a migraine at any point in the migraine cycle. Based on research to date, including the FREEDOM-301 trial, the company believes the unique pharmacokinetic profile of LEVADEX has the potential to effectively treat migraines, while minimizing the side effects commonly seen with DHE and other currently available medicines.

About Migraine

Common symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound). According to the National Headache Foundation, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies. Migraine patients report that currently approved drugs do not fully meet their needs due to slow onset of action, short duration of effect, inconsistent response and unacceptable side effect profiles. The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at

LEVADEX and TEMPO are trademarks of MAP Pharmaceuticals, Inc.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the following: risks related to the failure to achieve favorable clinical outcomes and to have the company's LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 and available at

    Lisa Borland
    MAP Pharmaceuticals, Inc.
    (650) 386-3122

    Nicole Foderaro
    Invigorate Communications
    (415) 946-1058

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SAGE to publish leading international headache journal Cephalalgia
2. High-Octane Caffeine May Trigger Headaches
3. Children with headache
4. Surgery for Neck Pain May Also Relieve Headaches
5. Jefferson Headache Center study shows novel, orally inhaled migraine therapy effective
6. Neck surgery for cervical spine disorders found to alleviate associated headaches
7. Neck Surgery for Cervical Spine Disorders Found to Alleviate Associated Headaches
8. Many Kids Outgrow Chronic Headaches
9. Viles & Beckman, LLC: Stop Your Headache NOT Your Liver
10. EHE International Supports the National Headache Foundation
11. New Online Tool Helps People With Headache Take Control, Get Relief
Post Your Comments:
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: